Clinical Project Manager Ii - Oncology

CLINICAL PROJECT MANAGER II – ONCOLOGY

Syneos Health is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

Our Clinical Development model brings the customer and the patient to the center of everything we do. We are continuously looking for ways to simplify and streamline our work to not only make Syneos Health easier to work with, but to make us easier to work for.

Whether you join us in a functional service provider partnership or a full‑service environment, you’ll collaborate with passionate problem solvers, innovating as a team to help our customers achieve their goals. We are agile and driven to accelerate the delivery of therapies, because we are passionate about changing lives.

• Support and partner with Clinical Study Leads and cross‑functional study teams on global oncology trials.
• Lead day‑to‑day study management activities across study startup, conduct, maintenance, and closeout.
• Manage study timelines, deliverables, risks, and issue resolution.
• Oversee external vendors, CROs, central laboratories, imaging vendors, and specialty providers.
• Coordinate Clinical Trial Team (CTT) meetings and drive action item follow‑up.
• Support study‑level planning, forecasting, and operational strategy execution.
• Monitor study performance metrics and proactively identify areas requiring intervention.
• Ensure inspection readiness and compliance with applicable regulations and sponsor requirements.
• Collaborate with stakeholders across Clinical Operations, Data Management, Biostatistics, Medical Monitoring, Regulatory Affairs, Safety, Supply Chain, and Quality.
• Contribute to study status reporting and executive‑level communications.
• Support achievement of study milestones, enrollment targets, database locks, and study closeout activities.

• Bachelor’s degree in a scientific, healthcare, or related field.
• 3+ years of Clinical Project Management experience supporting global oncology clinical trials.
• Experience managing studies across multiple countries and regions (North America, Europe, Asia‑Pacific, Latin America, or other global regions).
• Vendor management experience required.
• Strong understanding of clinical trial operations and study lifecycle management.
• Experience supporting Phase I, Phase II, Phase III, and/or Phase IV oncology studies.
• Strong working knowledge of ICH‑GCP guidelines and clinical research regulations.
• Proficiency with Microsoft Office Suite.
• Ability to work effectively within global, cross‑functional matrix organizations.

• Experience independently leading global oncology studies.
• Experience supporting complex, multi‑regional Phase II and Phase III programs.
• Experience with early‑phase oncology studies (Phase I/Ib).
• Experience with immuno‑oncology, targeted therapies, cell therapy, or hematologic malignancies.
• Familiarity with CTMS, eTMF, IRT/RTSM, and clinical data review platforms.
• Experience working in sponsor‑dedicated or FSP environments.

• Non‑Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)
• Breast Cancer
• Ovarian Cancer
• Cervical Cancer
• Endometrial Cancer
• Prostate Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Gastric Cancer
• Esophageal Cancer
• Hepatocellular Carcinoma (HCC)
• Melanoma
• Renal Cell Carcinoma (RCC)
• Bladder Cancer
• Head and Neck Cancer
• Thyroid Cancer
• Sarcoma
• Gynecologic Malignancies

• Multiple Myeloma
• Acute Myeloid Leukemia (AML)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphocytic Leukemia (CLL)
• Chronic Myeloid Leukemia (CML)
• Hodgkin Lymphoma
• Non‑Hodgkin Lymphoma
• Myelodysplastic Syndromes (MDS)
• Myeloproliferative Neoplasms (MPN)

• Immuno‑Oncology
• Cell and Gene Therapy
• CAR‑T Programs
• Bispecific Antibodies
• Antibody Drug Conjugates (ADCs)
• Precision Medicine / Biomarker‑Driven Studies

• Phase I / First‑in‑Human Studies
• Phase I/Ib Dose Escalation Studies
• Phase II Proof‑of‑Concept Studies
• Phase II/III Registrational Studies
• Phase III Global Pivotal Trials
• Phase IV and…